Abstract
Aflibercept plus FOLFIRI as second-line therapy in metastatic colorectal cancer (mCRC) during pandemic COVID-19: a real-world experience
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
